FR3058732B1 - Alpha-1,3-(3,6-anhydro)-d-galactosidases et leur utilisation pour hydrolyser des polysaccharides - Google Patents

Alpha-1,3-(3,6-anhydro)-d-galactosidases et leur utilisation pour hydrolyser des polysaccharides Download PDF

Info

Publication number
FR3058732B1
FR3058732B1 FR1661157A FR1661157A FR3058732B1 FR 3058732 B1 FR3058732 B1 FR 3058732B1 FR 1661157 A FR1661157 A FR 1661157A FR 1661157 A FR1661157 A FR 1661157A FR 3058732 B1 FR3058732 B1 FR 3058732B1
Authority
FR
France
Prior art keywords
anhydro
protein
activity
oligocarraghenans
carrageenans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1661157A
Other languages
English (en)
Other versions
FR3058732A1 (fr
Inventor
Elizabeth Ficko-Blean
Robert Larocque
Gaelle Correc
Mirjam Czjzek
Gurvan Michel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie Paris 6
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie Paris 6
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Pierre et Marie Curie Paris 6 filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1661157A priority Critical patent/FR3058732B1/fr
Priority to PCT/FR2017/053144 priority patent/WO2018091836A1/fr
Publication of FR3058732A1 publication Critical patent/FR3058732A1/fr
Application granted granted Critical
Publication of FR3058732B1 publication Critical patent/FR3058732B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0036—Galactans; Derivatives thereof
    • C08B37/0042—Carragenan or carragen, i.e. D-galactose and 3,6-anhydro-D-galactose, both partially sulfated, e.g. from red algae Chondrus crispus or Gigantia stellata; kappa-Carragenan; iota-Carragenan; lambda-Carragenan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne l'isolement, la purification et la caractérisation d'une protéine ayant une nouvelle activité enzymatique, à savoir une activité a-1,3-(3,6-anhydro)-D-galactosidase. Cette protéine est utile pour hydrolyser des polysaccharides et oligosaccharides contenant des motifs beta-carrabioses (non-sulfatés), qu'ils soient présent naturellement (exemple des carraghénanes extraits des algues rouges du genre Tichocarpus et de Furcellaria) ou introduit artificiellement par désulfatation chimique ou enzymatique (par exemple à partir des kappa- et iota-carraghénanes). L'activité cette protéine démontrée sur des oligocarraghénanes de structure hybride kappa/beta permet par exemple de produire le monosaccharide 3,6-anhydro-D-galactose et des oligocarraghénanes impairs de taille définie de la série carrabiose, c'est-à-dire qu'ils ont un résidu D-galactose à l'extrémité non-réductrice.
FR1661157A 2016-11-17 2016-11-17 Alpha-1,3-(3,6-anhydro)-d-galactosidases et leur utilisation pour hydrolyser des polysaccharides Active FR3058732B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1661157A FR3058732B1 (fr) 2016-11-17 2016-11-17 Alpha-1,3-(3,6-anhydro)-d-galactosidases et leur utilisation pour hydrolyser des polysaccharides
PCT/FR2017/053144 WO2018091836A1 (fr) 2016-11-17 2017-11-17 Alpha-1,3-(3,6-ANHYDRO)-D-GALACTOSIDASES ET LEUR UTILISATION POUR HYDROLYSER DES POLYSACCHARIDES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1661157A FR3058732B1 (fr) 2016-11-17 2016-11-17 Alpha-1,3-(3,6-anhydro)-d-galactosidases et leur utilisation pour hydrolyser des polysaccharides
FR1661157 2016-11-17

Publications (2)

Publication Number Publication Date
FR3058732A1 FR3058732A1 (fr) 2018-05-18
FR3058732B1 true FR3058732B1 (fr) 2021-01-01

Family

ID=58547574

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1661157A Active FR3058732B1 (fr) 2016-11-17 2016-11-17 Alpha-1,3-(3,6-anhydro)-d-galactosidases et leur utilisation pour hydrolyser des polysaccharides

Country Status (2)

Country Link
FR (1) FR3058732B1 (fr)
WO (1) WO2018091836A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730651A1 (fr) * 2012-11-08 2014-05-14 Centre National de la Recherche Scientifique (CNRS) Kappa carraghénane sulfatase, procédé de fabrication et utilisation

Also Published As

Publication number Publication date
FR3058732A1 (fr) 2018-05-18
WO2018091836A1 (fr) 2018-05-24

Similar Documents

Publication Publication Date Title
Berezin Neutrophil extracellular traps: The core player in vascular complications of diabetes mellitus
US10633683B2 (en) Gelling dextran ethers
Wang et al. Structure and biosynthesis of free lipid A molecules that replace lipopolysaccharide in Francisella tularensis subsp. novicida
JP2017510274A5 (fr)
MA39225A1 (fr) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
MA41179A (fr) Composés inhibiteurs de parg
Reina et al. 1, 2‐Mannobioside mimic: synthesis, DC‐SIGN interaction by NMR and docking, and antiviral activity
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
AU2017236063A1 (en) Monoclonal antibodies against the active site of factor XI and uses thereof
JP2021503953A5 (fr)
MA30343B1 (fr) Composition immunogene
EA201990091A1 (ru) Способ получения и очистки натриевой соли гиалуроновой кислоты
KR100736510B1 (ko) 당사슬 아스파라긴 유도체, 당사슬 아스파라긴, 당사슬 및그들의 제조법
WO2023101722A8 (fr) Nouveaux analogues de psilocine aza-substitués et procédés pour les synthétiser
WO2015148440A8 (fr) Production de polymères de glucane à partir de sources alternatives de saccharose
HUP0003021A2 (hu) Szulfonamidszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
MA39821B1 (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
Bhuvanachandra et al. New class of chitosanase from Bacillus amyloliquefaciens for the generation of chitooligosaccharides
CN104231085A (zh) 靶向特异性补体系统抑制剂、其制备方法及应用
FR3058732B1 (fr) Alpha-1,3-(3,6-anhydro)-d-galactosidases et leur utilisation pour hydrolyser des polysaccharides
CL2023002393A1 (es) Anticuerpos anti-cd30l y usos de estos
MX2021005248A (es) Anticuerpos contra cd73 activadores de células b.
Crawford et al. Synthetic glycans reveal determinants of antibody functional efficacy against a fungal pathogen
Ellsworth et al. Convergent recruitment of adamalysin-like metalloproteases in the venom of the red bark centipede (Scolopocryptops sexspinosus)
Shaik et al. QSAR and molecular docking studies on a series of cinnamic acid analogues as epidermal growth factor receptor (EGFR) inhibitors

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180518

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8